OPKO 1400

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:activeDuring gptkb:parathyroid_hormone
gptkbp:administrativeDivision daily
gptkbp:availability prescription only
gptkbp:clinicalTrials Phase 3
ongoing studies
positive outcomes
multiple sites
demonstrated in studies
long-term management
treatment of low calcium levels
recommended for specific patient populations
gptkbp:community_service available through manufacturer
gptkbp:communityPartnerships collaborations with universities
gptkbp:contraindication rare occurrences
hypersensitivity to the active ingredient
gptkbp:date FDA_approved
gptkbp:developedBy gptkb:OPKO_Health,_Inc.
gptkbp:dosageForm injection
gptkbp:drugInterdiction none significant
subcutaneous absorption
increases calcium levels in blood
gptkbp:educational_programs provided to healthcare professionals
gptkbp:formulation liquid
sterile solution
gptkbp:hasPopulation adults
gptkbp:healthcare important for adherence
https://www.w3.org/2000/01/rdf-schema#label OPKO 1400
gptkbp:insuranceAccepted may be covered
gptkbp:is_monitored_by calcium levels
gptkbp:lastProduced 2016
gptkbp:mandates chronic hypoparathyroidism
gptkbp:manufacturer gptkb:Miami,_Florida
gptkb:OPKO_Health,_Inc.
gptkbp:market available in pharmacies
gptkbp:marketedAs brand name
gptkbp:offers varies by location
gptkbp:packaging vial
gptkbp:patentStatus patented
gptkbp:produces gptkb:United_States
gptkbp:regulatoryCompliance granted_by_FDA
gptkbp:research_areas hormone replacement therapy
gptkbp:researchAndDevelopment ongoing
gptkbp:researchFocus endocrine disorders
gptkbp:route intravenous
gptkbp:safetyFeatures generally well tolerated
gptkbp:sideEffect headache
nausea
injection site reactions
gptkbp:storage refrigerated
gptkbp:supplyChain managed_by_OPKO_Health,_Inc.
gptkbp:targets hypoparathyroidism
gptkbp:usedFor diagnosing diseases